Filing identity and business context
Important mismatch: The supplied filing is Avista Healthcare Public Acquisition Corp.’s Form 10-Q for the quarter ended June 30, 2017—not an Organogenesis Holdings Inc. filing. Avista was a blank-check company seeking a business combination, with a stated focus on healthcare. It had not begun operating activities and reported no operating revenue.
Financial results and position
| Metric | Three months ended June 30, 2017 | Six months ended June 30, 2017 |
|---|---|---|
| Operating costs | $221,808 | $440,456 |
| Trust interest income | $602,142 | $961,653 |
| Net income | $380,334 | $521,197 |
| Net income per share, basic and diluted | $0.04 | $0.06 |
| Operating cash flow | — | $48,968 |
For the comparable 2016 periods, Avista reported losses of $500 for the quarter and $16,050 for the six months, with no interest income. Revenue and operating margins are not meaningful because the company had no operating business. At June 30, 2017, reported cash was $286,458; current assets were $602,920 and current liabilities were $85,825. The balance sheet showed $310.375 million in trust investments and $586,653 of accrued trust interest receivable. Total liabilities were $10.936 million, including $10.850 million of deferred underwriting commission. The filing reported no long-term debt.
Cash declined by $753,610 during the six months, ending at $286,458. The company reported $295.629 million of Class A shares subject to possible redemption, classified outside permanent shareholders’ equity; shareholders’ equity was $5.0 million.
Changes versus prior comparable periods
- Net results moved from small losses in 2016 to income in 2017, driven by interest earned on the trust assets; operating costs also increased.
- Six-month operating cash flow was $48,968 in 2017 versus zero in 2016, while trust reinvestment and offering-cost payments contributed to the cash decline.
- The filing says the company began earning trust interest in January 2017. No operating revenue was expected before a business combination.
Outlook, risks and notable items
- Management said it believed available resources were sufficient to pursue a business combination by October 14, 2018, the 24-month deadline. If no transaction is completed by then, the company must wind up and redeem public shares, subject to applicable claims and expenses.
- Public shareholders could redeem shares in connection with a business combination. The company was required to have at least $5,000,001 of net tangible assets upon closing; a target or targets generally had to meet Nasdaq’s 80% fair-market-value test.
- Management was reviewing potential targets but said it could not determine whether a transaction would be completed. The filing warns that target-search costs could exceed estimates and additional financing might be needed. A sponsor note allowing borrowing up to $300,000 was issued after quarter-end; no amount had been drawn. Affiliate administrative fees were being deferred until a business combination.
- Trust assets were invested in short-term U.S. Treasury bills. Management stated that interest-rate exposure was not material. A key disclosed risk is that third-party claims could reduce trust funds; the sponsor’s indemnity may be difficult to collect because its ability to pay was not verified.
- The company reported no material change to previously disclosed risk factors, no legal proceedings, and effective disclosure controls. No material change in internal control over financial reporting was reported.
Investor facts to verify
- Confirm the intended issuer: this filing identifies Avista Healthcare Public Acquisition Corp., not Organogenesis Holdings Inc.
- Reconcile working-capital cash: the filing reports $286,458 of cash but separately states $200,633 was available for working capital; it does not clearly explain the difference.
- Reconcile trust-account amounts: the balance sheet lists $310.375 million of trust investments plus $586,653 of accrued interest receivable, while the notes and MD&A cite $310.962 million held in trust and elsewhere describe $310.375 million as the trust balance.
- Review the business-combination timeline, redemption terms, deferred underwriting commission, and sponsor indemnity capacity.